All Articles

First-Line Toripalimab Combined with Chemotherapy Conveys Significant Benefits in Patients with Esophageal Squamous-Cell Carcinoma

Recently released clinical trial results show that bavituximab in combination with pembrolizumab had promising antitumor activity and was well-tolerated in patients with advanced gastric or gastroesophageal cancer.

Gastrointestinal Cancers

Progression-Free Survival Improved in Patients with HER2-Negative Recurrent or Advanced Gastric or Gastroesophageal Junction Cancer Receiving Nivolumab plus Chemotherapy

Patients with treatment-naïve advanced or metastatic esophageal squamous-cell carcinoma receiving combination toripalimab and chemotherapy saw significant progression-free survival and overall survival improvement.

Gastrointestinal Cancers

PET/CT Imaging in Prostate Cancer Patients

Clinical trial results demonstrate nivolumab combined with chemotherapy conveys improvement in overall response rate and progression-free survival in patients with recurrent or advanced gastric cancer.

PSMA PET Imaging in Patients with Oligometastatic Prostate Cancer

PET/CT Imaging in Prostate Cancer Patients

Dr Neal Shore discusses the importance of PSMA PET imaging across a range of PSA values and how PYLARIFY® (piflufolastat F 18) will affect imaging of patients with oligometastatic prostate cancer.

PYLARIFY and Next-Generation Imaging

By Neal D. Shore, MD

PET/CT Imaging in Prostate Cancer Patients

Dr Neal Shore elaborates on the ability of PYLARIFY® (piflufolastat F 18) to detect metastases and the practical aspects of next-generation imaging.

PSMA-Targeted Imaging for Prostate Cancer Treatment

By Neal D. Shore, MD

Best Practices in GU Navigation

Dr Neal Shore discusses the rationale of prostate-specific membrane antigen (PSMA) PET/CT to guide prostate cancer treatment.

A New Era of Treatment Options for Patients with Advanced Renal-Cell Cancer

By Laura Wood, RN, MSN, OCN; Megan Price, MSN, APRN, FNP-C; Virginia Seery, CRNP, MSN

Lung Cancer Molecular Testing Rates Similar Across Patient Age-Groups

Combinations of agents have replaced sunitinib as first-line therapy for advanced renal-cell cancer. Laura Wood, RN, MSN, OCN; Megan Price, MSN, APRN, FNP-C; and Virginia Seery, MSN, RN, ANP-BC, AOCNP, discuss their best practices for helping patients get the most benefit out of combination therapy for their advanced renal-cell cancer diagnosis.

Lung Cancer

Gene Mutation Rates in Lung Cancer Correlate with Different Clinical Indicators

Researchers reported that molecular testing in patients with non–small-cell lung cancer aged ≥70 years is performed at the same proportions as in younger patients.

Lung Cancer

Low-Dose Computed Tomography Lung Cancer Screening Public Health and Economic Benefits

Analysis of EGFR, KRAS, and PIK3CA gene mutation rates in patients with lung cancer revealed a correlation with clinical characteristics that may have a significant effect on personalized cancer treatment.

Lung Cancer